These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 18682687)
1. EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Thomas SL; Zhong D; Zhou W; Malik S; Liotta D; Snyder JP; Hamel E; Giannakakou P Cell Cycle; 2008 Aug; 7(15):2409-17. PubMed ID: 18682687 [TBL] [Abstract][Full Text] [Related]
2. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma. Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of the NF-κB signaling pathway by the curcumin analog, 3,5-Bis(2-pyridinylmethylidene)-4-piperidone (EF31): anti-inflammatory and anti-cancer properties. Olivera A; Moore TW; Hu F; Brown AP; Sun A; Liotta DC; Snyder JP; Yoon Y; Shim H; Marcus AI; Miller AH; Pace TW Int Immunopharmacol; 2012 Feb; 12(2):368-77. PubMed ID: 22197802 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. Kasinski AL; Du Y; Thomas SL; Zhao J; Sun SY; Khuri FR; Wang CY; Shoji M; Sun A; Snyder JP; Liotta D; Fu H Mol Pharmacol; 2008 Sep; 74(3):654-61. PubMed ID: 18577686 [TBL] [Abstract][Full Text] [Related]
5. Curcumin analog EF24 induces apoptosis via ROS-dependent mitochondrial dysfunction in human colorectal cancer cells. He G; Feng C; Vinothkumar R; Chen W; Dai X; Chen X; Ye Q; Qiu C; Zhou H; Wang Y; Liang G; Xie Y; Wu W Cancer Chemother Pharmacol; 2016 Dec; 78(6):1151-1161. PubMed ID: 27787644 [TBL] [Abstract][Full Text] [Related]
6. The curcumin analog EF24 targets NF-κB and miRNA-21, and has potent anticancer activity in vitro and in vivo. Yang CH; Yue J; Sims M; Pfeffer LM PLoS One; 2013; 8(8):e71130. PubMed ID: 23940701 [TBL] [Abstract][Full Text] [Related]
7. Biological Effects of EF24, a Curcumin Derivative, Alone or Combined with Mitotane in Adrenocortical Tumor Cell Lines. Bertazza L; Barollo S; Mari ME; Faccio I; Zorzan M; Redaelli M; Rubin B; Armanini D; Mian C; Pezzani R Molecules; 2019 Jun; 24(12):. PubMed ID: 31212829 [TBL] [Abstract][Full Text] [Related]
8. Activation of the p38 pathway by a novel monoketone curcumin analog, EF24, suggests a potential combination strategy. Thomas SL; Zhao J; Li Z; Lou B; Du Y; Purcell J; Snyder JP; Khuri FR; Liotta D; Fu H Biochem Pharmacol; 2010 Nov; 80(9):1309-16. PubMed ID: 20615389 [TBL] [Abstract][Full Text] [Related]
9. ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma. Carew JS; Esquivel JA; Espitia CM; Schultes CM; Mülbaier M; Lewis JD; Janssen B; Giles FJ; Nawrocki ST PLoS One; 2012; 7(1):e31120. PubMed ID: 22295124 [TBL] [Abstract][Full Text] [Related]
10. A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies. Bisht S; Schlesinger M; Rupp A; Schubert R; Nolting J; Wenzel J; Holdenrieder S; Brossart P; Bendas G; Feldmann G J Nanobiotechnology; 2016 Jul; 14(1):57. PubMed ID: 27401816 [TBL] [Abstract][Full Text] [Related]
11. Multiple anticancer activities of EF24, a novel curcumin analog, on human ovarian carcinoma cells. Tan X; Sidell N; Mancini A; Huang RP; Shenming Wang ; Horowitz IR; Liotta DC; Taylor RN; Wieser F Reprod Sci; 2010 Oct; 17(10):931-40. PubMed ID: 20693500 [TBL] [Abstract][Full Text] [Related]
12. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Escuin D; Kline ER; Giannakakou P Cancer Res; 2005 Oct; 65(19):9021-8. PubMed ID: 16204076 [TBL] [Abstract][Full Text] [Related]
13. MicroRNA-33b, upregulated by EF24, a curcumin analog, suppresses the epithelial-to-mesenchymal transition (EMT) and migratory potential of melanoma cells by targeting HMGA2. Zhang P; Bai H; Liu G; Wang H; Chen F; Zhang B; Zeng P; Wu C; Peng C; Huang C; Song Y; Song E Toxicol Lett; 2015 May; 234(3):151-61. PubMed ID: 25725129 [TBL] [Abstract][Full Text] [Related]
14. Microtubules regulate hypoxia-inducible factor-1α protein trafficking and activity: implications for taxane therapy. Carbonaro M; Escuin D; O'Brate A; Thadani-Mulero M; Giannakakou P J Biol Chem; 2012 Apr; 287(15):11859-69. PubMed ID: 22367210 [TBL] [Abstract][Full Text] [Related]
15. In vivo and in vitro suppression of hepatocellular carcinoma by EF24, a curcumin analog. Liu H; Liang Y; Wang L; Tian L; Song R; Han T; Pan S; Liu L PLoS One; 2012; 7(10):e48075. PubMed ID: 23118928 [TBL] [Abstract][Full Text] [Related]
16. M410, a combretastatin A4 analogue, disrupts microtubules and inhibits HIF-1α in human breast cancer cells. Yang H; Xia Q; Zou Y; Wang K; Jiang W; Cai Y Oncol Rep; 2015 Jul; 34(1):334-40. PubMed ID: 25976207 [TBL] [Abstract][Full Text] [Related]
17. The curcumin analog EF24 is a novel senolytic agent. Li W; He Y; Zhang R; Zheng G; Zhou D Aging (Albany NY); 2019 Jan; 11(2):771-782. PubMed ID: 30694217 [TBL] [Abstract][Full Text] [Related]
18. Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity. Subramaniam D; May R; Sureban SM; Lee KB; George R; Kuppusamy P; Ramanujam RP; Hideg K; Dieckgraefe BK; Houchen CW; Anant S Cancer Res; 2008 Mar; 68(6):1962-9. PubMed ID: 18339878 [TBL] [Abstract][Full Text] [Related]
19. Curcumin analogue EF24 prevents alveolar epithelial cell senescence to ameliorate idiopathic pulmonary fibrosis via activation of PTEN. Zhang Y; Liu J; Zheng R; Hou K; Zhang Y; Jia T; Lu X; Samarawickrama PN; Jia S; He Y; Liu J Phytomedicine; 2024 Oct; 133():155882. PubMed ID: 39096545 [TBL] [Abstract][Full Text] [Related]
20. The Curcumin Analog EF24 is Highly Active Against Chemotherapy- Resistant Melanoma Cells. He Y; Li W; Zhang J; Yang Y; Qian Y; Zhou D Curr Cancer Drug Targets; 2021; 21(7):608-618. PubMed ID: 33655859 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]